Drugs / latanoprost free acid
last change Sep 2023 re-read 3 minutes ago

latanoprost free acid

Developed for
ocular hypertension · open-angle glaucoma
Investigated by
PolyActiva Pty Ltd

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05333419 Mar 2022 → Jun 2023 ocular hypertension, open-angle glaucoma PolyActiva Pty Ltd Completed No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2022-03-17 PolyActiva Pty Ltd Results PolyActiva presents positive clinical trial results polyactiva.com ↗
The accepted poster, “Interim Phase 2a Clinical Study Results with PA5108 Latanoprost Ocular Implant for the Treatment of Glaucoma” will be presented by Associate Professor Michael Coote , MD, a leading glaucoma specialist at Melbourne Eye Specialists and a principal investigator of the study.
2020-11-05 PolyActiva Pty Ltd Results PolyActiva successfully completes initial clinical trial polyactiva.com ↗
The device was well tolerated in all 8 patients with no significant safety findings.
2019-07-24 PolyActiva Pty Ltd Results PolyActiva completes recruitment in key Phase I polyactiva.com ↗
To date, our Phase I study has demonstrated that our implant is safe and well tolerated and provides treatment for a six-month period before it biodegrades completely.

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as latanoprost free acid “PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called...” NCT05333419 ↗
Route Other “placed in the anterior (front) chamber of the eye” NCT05333419 ↗